**ASSOCIATION BETWEEN SARCOPENIA AND DIABETES:**

**A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES**

Nicola Veronese1, Damiano Pizzol2, Jacopo Demurtas3, Pinar Soysal4, Lee Smith5, Cornel Sieber6, Timo Strandberg7, Isabelle Bourdel-Marchasson8, Alan Sinclair9, Mirko Petrovic10, Stefania Maggi1 on behalf of the Special Interest Groups of Systematic Reviews and Meta-Analysis for Healthy Aging, Diabetes, Sarcopenia of European Geriatric Medicine Society (EuGMS)

1. National Research Council, Neuroscience Institute, Aging Branch, Padova, Italy.

2. Operational Research Unit, Doctors with Africa, Mozambique.

3. Primary Care Department, Azienda USL Toscana Sud Est, 58100 Grosseto, Italy.

4. Department of Geriatric Medicine, Bezmialem Vakif University, Istanbul, Turkey.

5. The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK, CB1 1PT

6. Institute for Biomedicine of Ageing (IBA), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), D-90408 Nürnberg, Germany.

7. University of Helsinki, Clinicum, and Helsinki University Hospital, Finland; Center for Life Course Health Research, University of Oulu, Finland.

8. CNRS/ University of Bordeaux, RMSB, Bordeaux, France; ,; Pôle de gérontologie clinique, CHU de Bordeaux, Bordeaux, France.

9. Diabetes Frail Ltd and King's College, London, United Kingdom.

10. Department of Internal Medicine and Paediatrics, Section of Geriatrics, Ghent University, Ghent, Belgium.

**Corresponding Author:**

Nicola Veronese, MD. National Research Council, Neuroscience Institute, Aging Branch. Via Giustiniani, 2 35128 Padova, Italy. Phone: +390498211746; Fax: +390498211218 Email: ilmannato@gmail.com

**KEY SUMMARY POINTS**

**Aim**

To summarize the prevalence of diabetes in people with sarcopenia (and vice versa) through a meta-analytic approach of available observational studies.

**Findings**

In this work, we have presented the findings of the first full methodological systematic review and meta-analysis of observational studies exploring the relationship between diabetes and sarcopenia. Our findings overall emphasize the reciprocal relationship between diabetes and sarcopenia in terms of risk of occurrence, that is sarcopenia increases the risk of diabetes being present and vice versa.

**Message**

This study provides support for further research into the prognosis of people with both diabetes and sarcopenia and the value of interventional strategies in sarcopenia to minimize adverse outcomes such as premature death, hospitalization and disability.

**ABSTRACT**

**Purpose**: Sarcopenia and diabetes are two common conditions in older people. Some recent literature has proposed that these two conditions can be associated. However, to date, no attempt has been made to collate this literature. Therefore, we aimed to summarize the prevalence of sarcopenia in diabetes (and vice versa) and the prevalence of sarcopenia in people with diabetes complications, through a systematic review and meta-analysis.

**Methods**: Two authors searched major electronic databases from inception until March 2019 for case control/cross-sectional/longitudinal studies investigating sarcopenia and diabetes. The strength of the reciprocal associations between sarcopenia and diabetes was assessed through odds ratios (ORs) with 95% confidence intervals (CIs), adjusted for potential confounders, where possible.

**Results**: From 953 potential eligible articles, 20 were included in the systematic review, with 17 providing data for meta-analysis. Overall, 54,676 participants were included (mean age= 65.4 years). Diabetic participants had an increased prevalence of sarcopenia compared to controls (n=10; OR=1.635; 95%CI: 1.204-2.220; p=0.002; I2=67%), whilst, after adjusting for potential confounders, sarcopenia was associated with an increased odds of having diabetes (OR=2.067; 95%CI: 1.396-3.624; p<0.0001; I2=0%). In 1,868 diabetic participants with a complication, there was an increased prevalence of sarcopenia (OR=2.446; 95%CI: 1.839-3.254; p<0.0001; I2=0%), as compared with those with no complication. Very limited data existed regarding studies with a longitudinal design.

**Conclusions**: Our study suggests a bi-directional association between diabetes and sarcopenia, particularly when diabetic complications are present.

**Keywords**: diabetes; sarcopenia; physical performance; meta-analysis.

**INTRODUCTION**

The prevalence of diabetes mellitus (DM) is increasing worldwide, particularly in older age. This is due in part to increased survival owing to advances in the management of DM and of DM comorbidity [[1](#_ENREF_1), [2](#_ENREF_2)] and in part due to increasing population age and urbanisation of lifestyle.[[3](#_ENREF_3)] During the last decade there has been increasing recognition of other diabetes-related complications such as frailty and sarcopenia which have become areas of new research interest. [[4](#_ENREF_4)]

Sarcopenia is the pathological loss of skeletal muscle mass associated with the loss of power and function.[[5](#_ENREF_5), [6](#_ENREF_6)] It is reported that sarcopenia affects approximately 10% of older people[[7](#_ENREF_7)] and this condition, similarly to diabetes, is associated with several negative outcomes in older people, including premature mortality, re-hospitalization and disability.[[8](#_ENREF_8), [9](#_ENREF_9)] As skeletal muscle plays a major role in glucose metabolism and if altered can lead to insulin resistance [[10](#_ENREF_10)], it has been postulated that sarcopenia and diabetes may be associated.[[4](#_ENREF_4)] Epidemiological studies suggest that diabetes is related to an accelerated decrease in physical performance and muscle strength parameters [[11-13](#_ENREF_11)] and consequently may lead to sarcopenia, whilst conversely, sarcopenic patients can be at an increased risk of diabetes, e.g. for higher sedentary behaviour prevalence. [[14](#_ENREF_14)]

Studies of sarcopenia in older people with diabetes are few and there is a lack of an in depth analysis of observational studies in this area. [[15](#_ENREF_15)] Given this background, we aimed to summarize the prevalence of sarcopenia in diabetes (and vice versa) and the prevalence of sarcopenia in people with diabetes and macro- or micro-angiopathy complications versus those without, through a systematic review and meta-analysis of observational studies regarding this topic.

**METHODS**

This systematic review adhered to the PRISMA [[16](#_ENREF_16)] and MOOSE[[17](#_ENREF_17)] statements and followed a structured, but unpublished protocol.

***Data sources and literature search strategy***

Two investigators (NV and DP) independently conducted a literature search using PubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials and Clinicaltrials.gov without language restriction, from database inception until 01st March 2019 for observational studies investigating the prevalence of sarcopenia in participants with diabetes (vs. those without) and vice versa. Moreover, we included studies assessing the prevalence of sarcopenia in participants with diabetes and its usual macro- or micro-angiopathy complications vs. people with diabetes but without complications. Any inconsistencies were resolved by consensus with a third author (SM).

In PubMed, the following search strategy was used: “diabetes [tiab] AND sarcopenia [tiab]”. Conference abstracts and reference lists of included articles were hand-searched to identify any potential additional relevant articles.

***Study selection***

Inclusion criteria for this meta-analysis were: i) diagnosis of diabetes (e.g. self-reported, according to the American Diabetes Association criteria [[18](#_ENREF_18)]) not limited only to type 2; ii) diagnosis of sarcopenia: in this case we included standardized methods of determining sarcopenia (e.g. Asia Working Group for Sarcopenia, AWGS[[19](#_ENREF_19)] or European Working Group on Sarcopenia in Older People, EWGSOP [[5](#_ENREF_5)] criteria) or diagnosis through body composition or muscle mass/physical performance parameters, according to validated criteria. Studies were excluded if: i) did not include humans; ii) did not report any meta-analysable data.

***Data extraction***

Two independent investigators (NV and DP) extracted key data from the included articles in a standardized Excel sheet. A third independent investigator (SM) checked the extracted data. For each article, we extracted data on authors, year of publication, country, setting, condition, number of participants, demographics (mean age, mean body mass index, BMI), diagnostic criteria for diabetes and sarcopenia, main findings for each paper, number and type of covariates used in multivariable analysis.

***Outcomes***

The primary outcomes considered were the prevalence of sarcopenia in diabetes and vice versa and the prevalence of sarcopenia in people with diabetes and macro- or micro-angiopathy complications (vs. those without). The data should be reported as number of events or as adjusted odds ratios (ORs).

***Assessment of study quality***

The Newcastle-Ottawa Scale (NOS) [[20](#_ENREF_20), [21](#_ENREF_21)] was used to assess study quality. The NOS assigns a maximum of 9 points based on 3 quality parameters: selection, comparability, and outcome, with a cut-off of ≤5 being indicative of high risk of bias. NOS scores were assessed by 2 investigators (DP, NV) and a consensus was reached in case of discrepancy. [[20](#_ENREF_20), [21](#_ENREF_21)]

***Data synthesis and statistical analysis***

All analyses were performed using Comprehensive Meta-Analysis (CMA) 3. Only outcomes having at least 3 studies were meta-analysed; the other outcomes were summarized descriptively.

The primary analysis compared the prevalence of sarcopenia in diabetes and vice versa and the prevalence of sarcopenia in people with diabetes and macro- or micro-angiopathy complications (vs. those without), applying a random-effect model.[[22](#_ENREF_22)] The data were reported as ORs with their 95% confidence intervals (CIs).

Heterogeneity across studies was assessed by the I2 metric. Given significant heterogeneity (I2 >50% and/or p<0.05) [[23](#_ENREF_23)] and having at least 10 studies for each outcome, meta-regression analyses were carried out, taking as moderators the following factors: mean age and the difference in mean age between diabetic and controls, NOS score, the diagnostic criteria of diabetes or sarcopenia.

Publication bias was assessed by a visual inspection of funnel plots and calculating the Egger bias test.[[24](#_ENREF_24)]We also reported the fail-safe number (i.e. the number of studies bringing alpha over the p-value) and trim and fill analyses were performed.[[25](#_ENREF_25)]

For all analyses, a p-value less than 0.05 was considered statistically significant.

**RESULTS**

***Search results***

As shown in **eFigure 1**, altogether, the searches gave 953 non-duplicated articles. After excluding 920 articles based on title/abstract review, 33 articles were retrieved for full text review. Among these, 20 studies were included in the systematic review [[26-45](#_ENREF_26)] and 17 of them in the meta-analysis: two studies, in fact, were longitudinal [[41](#_ENREF_41), [42](#_ENREF_42)] and another one adjusted estimates for the association between diabetic complications and sarcopenia, without reporting the prevalence of sarcopenia in those having diabetes complications.[[26](#_ENREF_26)]

***Study and patient characteristics***

**Table 1** summarizes the data regarding the included studies. Overall, 54,676 participants were included having a mean age of 65.4 years (SD=11.2), with a mean BMI of 25 (SD=3.7). Of the 20 studies included, the majority (n=14) were carried out in Asia. Seven studies investigated participants having type 2 diabetes and 6 studies used the criteria suggested by the AWGS that defined sarcopenia as low skeletal muscle mass plus low muscle strength and/or low physical performance according to predefined criteria.[[19](#_ENREF_19)] All the studies used diagnosis of diabetes validated by a physician or using medical data.

Looking to the main findings of the included articles, we observed a significant association between diabetes and sarcopenia and vice versa.

The median NOS was 6 (range: 3-8), indicating a sufficient quality of the studies included.

***Prevalence of sarcopenia in diabetes***

**Figure 1** reports the prevalence of sarcopenia in participants with diabetes versus controls. In patients with diabetes, the prevalence of sarcopenia was 28.4% (95%CI: 18.9-40.2), whilst in the control group was 18.7% (95%CI: 11.9-28.1). Ten studies were included, overall showing that diabetic participants had an increased prevalence of sarcopenia compared to controls (n=10; OR=1.635; 95%CI: 1.204-2.220; p=0.002; I2=67%). The meta-regression analysis (using as moderators mean age and the difference in mean age between diabetic and controls, NOS score, the diagnostic criteria of diabetes or sarcopenia) did not explain any of the heterogeneity found (details available upon request).

The Egger’s test suggested that there was a potential publication bias (=1.88±0.85; p=0.05). The trim and fill analysis suggested that, after trimming two studies at the left of the mean, the recalculated OR was 1.478 (95%CI: 1.080-2.026). The fail-safe number for this outcome was 63. Only one study reported data adjusted for potential confounders, substantially confirming these findings. [[45](#_ENREF_45)]

***Association between sarcopenia and diabetes***

**Figure 2** reports the association between sarcopenia and diabetes, adjusted for potential confounders. This analysis involved 37,396 participants. After adjusting for a median of 3 potential covariates (range: 0-7), sarcopenia was associated with an increased odds of having diabetes (OR=2.067; 95%CI: 1.396-3.624; p<0.0001; I2=0%). This outcome did not suffer on publication bias as revealed by the visual inspection of the funnel plots and/or using the Egger’s test (p-value >0.05). The fail-safe number was 9.

One study reported the association between sarcopenia at baseline (reported as the lowest tertile of handgrip strength at the baseline) and incident diabetes in the English Longitudinal Study of Ageing.[[41](#_ENREF_41)] After adjusting for 7 potential confounders, in more than 5,000 participants, the authors failed to find any significant association between these two conditions.

***Association between diabetes complications and sarcopenia***

Five studies reported the association between diabetes complications and the presence of sarcopenia. Retinopathy was the most common complication assessed. These studies included 1,868 participants and reported that diabetic people with a complication had an increased prevalence of sarcopenia when compared to diabetic people without (OR=2.446; 95%CI: 1.839-3.254; p<0.0001; I2=0%). This outcome did not suffer on publication bias as revealed by the visual inspection of the funnel plots and/or using the Egger’s test (p-value >0.05). The fail-safe number was 36.

One cross-sectional study confirmed these findings, using an OR adjusted for 11 potential confounders.[[26](#_ENREF_26)] Interestingly, one study reported the prospective association between sarcopenia at baseline and incident micro-albuminuria, again supporting the potential association between sarcopenia and poor renal function.[[42](#_ENREF_42)]

**DISCUSSION**

In this systematic review and meta-analysis which included 20 studies, we found that sarcopenia was more prevalent in diabetic patients (when compared to their counterparts without diabetes) and associated with an increased odds of having diabetes in 37,396 participants. Moreover, diabetic complications were associated with a higher frequency of sarcopenia, when compared to people with diabetes, but without any complication. In that sense, one longitudinal study suggests that sarcopenia can be associated with a decline in renal function. Taken together, these findings suggest a bidirectional association between diabetes and sarcopenia and that the presence of a diabetic complication can further increase the presence of sarcopenia.

The association between insulin resistance (as observed in type 2 diabetes), abdominal obesity and sarcopenia may be explained by several pathways, such as the loss of the anabolic action to insulin, the reduced insulin-inhibition of proteolysis, and the loss of anti-inflammation actions. Inflammation (particularly when associated with obesity) is an important determinant of sarcopenia, as we recently reported in a systematic review and meta-analysis regarding this topic.[[46](#_ENREF_46)] For example, TNF-α, which is highly expressed in adipose tissues in obese subjects may block muscle tissues differentiation leading to sarcopenia.[[47](#_ENREF_47)] Other works have reported that a reduction in oxidative type I fibres and a concomitant increase in glycolytic type IIb fibres, combined with aging effects on muscle, leads to an overall decrease in mitochondrial function and consequently an increase in insulin resistance and oxidative stress, finally leading to sarcopenia. [[47](#_ENREF_47), [4](#_ENREF_4)] Finally, insulin resistance may also alter the glycogen storage in type IIa muscle fibres, decreasing the efficiency of oxidative phosphorilation.[[48](#_ENREF_48)] In this sense, a study excluded from our meta-analysis since the cohort was already included (Korean Sarcopenic Obesity Study) and no meta-analysable data were available, reported that appendicular skeletal mass values were significantly decreased in patients with diabetes compared with subjects without diabetes.[[49](#_ENREF_49)]

From an epidemiological point of view, sarcopenia and diabetes seem to be reciprocally related and could share similar pathogenetic pathways. As diabetes leads to sarcopenia, as mentioned before, it is also possible that sarcopenia can lead to lower muscle glucose uptake, hyperglycaemia/ hyperinsulinaemia and finally to insulin resistance, precursors of diabetes.[[50](#_ENREF_50)] We have also reported that poor physical performance can be associated with an increased risk of diabetes.[[51](#_ENREF_51)] Muscle fat infiltration, a component that seems increasingly important in several aspects of geriatric medicine, might also lead to insulin resistance promoting both the development of sarcopenia and diabetes. [[51](#_ENREF_51)] On the contrary, in the only study including people with Latent Autoimmune Diabetes of Adults, we did not observe any significant difference in sarcopenia prevalence when compared to controls, overall suggesting that particularly insulin-resistance typical of type 2 diabetes is implicated in the development of sarcopenia. [[38](#_ENREF_38)] Chronic low-grade inflammation is another factor that can have a role in the development of both diabetes and sarcopenia.[[46](#_ENREF_46), [52](#_ENREF_52), [53](#_ENREF_53)]

Finally, we found that sarcopenia is more common in diabetic people with complications than in DM patients without complications. Even if this analysis is limited by the fact that all the complications were pooled together (micro and macro-vascular), these findings suggest a potential role of the vascular system in the development of sarcopenia.[[54](#_ENREF_54)] In one exploratory study, for example, the authors found that in sarcopenic patients there was a lower skeletal muscle capillarization that may contribute to the development of sarcopenia and reduced exercise capacity by limiting the diffusion of substrates essential for the muscle, such as oxygen, hormones, or nutrients. [[55](#_ENREF_55)] However, it is also possible that the complication profile depends on the mechanisms of diabetes itself and that the contribution of vascular factors, even if pivotal, is probably not enough to explain the link that we observed.

Our meta-analysis reports, however, some preliminary findings regarding the potential association between sarcopenia and diabetes and vice versa limited to cross-sectional and case-control studies. We can suggest that future longitudinal studies could specifically investigate, for example, the role of singular complication in predicting sarcopenia (e.g. neuropathy or renal failure) or the role of sarcopenia in predicting more rare forms of diabetes such as type 1 diabetes and LADA.

Findings from the present meta-analysis should be interpreted within its limitations. First, the results were heterogenous. Second, our findings were mainly based on case control or cross-sectional studies, whilst only two papers were longitudinal. Moreover, in case control and cross-sectional studies, the prevalence of sarcopenia in diabetes is not adjusted for potential confounders. Third, the diagnosis of sarcopenia was made through multidimensional tools only in 8 over 20 studies, whilst many others assessed sarcopenia only through muscle mass or muscle function parameters. Fourth, the majority of the studies included Asiatic people and the mean age was only 65 years, suggesting that further studies in more old people are needed. Finally, in the outcome characterized by a high heterogeneity (i.e. the prevalence of sarcopenia in diabetes), we were not able to find any significant moderator explaining this factor. In this regard, for example, it is possible that the higher presence of diabetic complications in people with diabetes than controls can contribute to explain the heterogeneity found in our analysis. For example, some authors suggest that neuropathy (a common and traditional complication of diabetes) can lead to sarcopenia. [[56](#_ENREF_56)]

In conclusion, our systematic review and meta-analysis indicated that sarcopenia and diabetes can be bi-directionally associated, even if the findings are mainly based on cross-sectional and case control studies. People with diabetic complications reported a significantly higher presence of sarcopenia compared to diabetic participants without complications. Since both diabetes and sarcopenia are two highly prevalent conditions in ageing populations, future longitudinal studies are needed to better explain this association.

**ACKNOWLEDGMENTS**

**Funding source:** None to declare.

**Ethical approval:** Not required since it is a review of already published works.

**Conflict of interest**: The authors have not conflict of interest to declare for this work.

**Informed consent:** For this type of study, formal consent is not required.

**REFERENCES**

1. Umegaki H. Sarcopenia and frailty in older patients with diabetes mellitus. Geriatrics & gerontology international. 2016;16(3):293-9.

2. Karjalainen M, Tiihonen M, Kautiainen H, Saltevo J, Haanpää M, Mäntyselkä P. Pain and self-rated health in older people with and without type 2 diabetes. European Geriatric Medicine. 2018;9(1):127-31.

3. Ogurtsova K, da Rocha Fernandes J, Huang Y, Linnenkamp U, Guariguata L, Cho N et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes research and clinical practice. 2017;128:40-50.

4. Sinclair AJ, Abdelhafiz AH, Rodríguez-Mañas L. Frailty and sarcopenia-newly emerging and high impact complications of diabetes. Journal of Diabetes and its Complications. 2017;31(9):1465-73.

5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and ageing. 2010;39(4):412-23. doi:10.1093/ageing/afq034.

6. Di Francesco V, Pellizzari L, Corrà L, Fontana G. The anorexia of aging: impact on health and quality of life. Geriatric Care. 2018;4(2). doi:10.4081/gc.2018.7324.

7. Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. Journal of Diabetes & Metabolic Disorders. 2017;16(1):21.

8. Beaudart C, Zaaria M, Pasleau F, Reginster J-Y, Bruyère O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PloS one. 2017;12(1):e0169548.

9. Zhao Y, Zhang Y, Hao Q, Ge M, Dong B. Sarcopenia and hospital-related outcomes in the old people: a systematic review and meta-analysis. Aging clinical and experimental research. 2019;31(1):5-14.

10. Greene NP, Brown JL, Rosa-Caldwell ME, Lee DE, Blackwell TA, Washington TA. Skeletal muscle insulin resistance as a precursor to Diabetes: Beyond glucoregulation. Current diabetes reviews. 2018;14(2):113-28.

11. Leenders M, Verdijk LB, van der Hoeven L, Adam JJ, Van Kranenburg J, Nilwik R et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. Journal of the American Medical Directors Association. 2013;14(8):585-92.

12. Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes care. 2007;30(6):1507-12.

13. Siviero P, Tonin P, Maggi S. Functional limitations of upper limbs in older diabetic individuals. The Italian Longitudinal Study on Aging. Aging clinical and experimental research. 2009;21(6):458-62.

14. Wilmot EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia. 2012;55(11):2895-905. doi:10.1007/s00125-012-2677.

15. Sinclair AJ, Rodriguez-Manas L. Diabetes and frailty: two converging conditions? Canadian journal of diabetes. 2016;40(1):77-83.

16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS medicine. 2009;6(7):e1000100-e. doi:10.1371/journal.pmed.1000100.

17. Stroup DF, Berlin Ja, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA : the journal of the American Medical Association. 2000;283:2008-12. doi:10.1001/jama.283.15.2008.

18. Association AD. 2. Classification and Diagnosis of Diabetes. Diabetes care. 2014;38(Supplement\_1):S8-S16. doi:10.2337/dc15-S005.

19. Chen L-K, Liu L-K, Woo J, Assantachai P, Auyeung T-W, Bahyah KS et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. Journal of the American Medical Directors Association. 2014;15(2):95-101.

20. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. (Available from: URL: [http://wwwohrica/programs/clinical\_epidemiology/oxfordasp)](http://wwwohrica/programs/clinical_epidemiology/oxfordasp%29). 2012:2012-. doi:10.2307/632432.

21. Luchini CS, Brendon; Solmi, Marco; Veronese, Nicola Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale World J Meta-Anal. 2017;5:80-4.

22. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21(11):1539-58. doi:10.1002/sim.1186.

23. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928. doi:10.1136/bmj.d5928.

24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315(September):629-34. doi:10.1136/bmj.316.7129.469.

25. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-63. doi:10.1111/j.0006-341x.2000.00455.x.

26. Yang R, Zhang Y, Shen X, Yan S. Sarcopenia associated with renal function in the patients with type 2 diabetes. Diabetes research and clinical practice. 2016;118:121-9. doi:10.1016/j.diabres.2016.06.023.

27. Murata Y, Kadoya Y, Yamada S, Sanke T. Sarcopenia in elderly patients with type 2 diabetes mellitus: prevalence and related clinical factors. Diabetology international. 2018;9(2):136-42. doi:10.1007/s13340-017-0339-6.

28. Fukuda T, Bouchi R, Takeuchi T, Nakano Y, Murakami M, Minami I et al. Association of diabetic retinopathy with both sarcopenia and muscle quality in patients with type 2 diabetes: a cross-sectional study. BMJ open diabetes research & care. 2017;5(1):e000404. doi:10.1136/bmjdrc-2017-000404.

29. Freitas VP, Passos RDS, Oliveira AA, Ribeiro IJS, Freire IV, Schettino L et al. Sarcopenia is associated to an impaired autonomic heart rate modulation in community-dwelling old adults. Arch Gerontol Geriatr. 2018;76:120-4. doi:10.1016/j.archger.2018.01.006.

30. Cheng Q, Hu J, Yang P, Cao X, Deng X, Yang Q et al. Sarcopenia is independently associated with diabetic foot disease. Scientific reports. 2017;7(1):8372. doi:10.1038/s41598-017-08972-1.

31. Celiker M, Selcuk MY, Olt S. Sarcopenia in diabetic nephropathy: a cross-sectional study. Romanian journal of internal medicine = Revue roumaine de medecine interne. 2018;56(2):102-8. doi:10.2478/rjim-2018-0003.

32. Wang T, Feng X, Zhou J, Gong H, Xia S, Wei Q et al. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. Scientific reports. 2016;6:38937. doi:10.1038/srep38937.

33. Ma J, Hwang SJ, McMahon GM, Curhan GC, McLean RR, Murabito JM et al. Mid-adulthood cardiometabolic risk factor profiles of sarcopenic obesity. Obesity (Silver Spring). 2016;24(2):526-34. doi:10.1002/oby.21356.

34. Lim HS, Park YH, Suh K, Yoo MH, Park HK, Kim HJ et al. Association between Sarcopenia, Sarcopenic Obesity, and Chronic Disease in Korean Elderly. J Bone Metab. 2018;25(3):187-93. doi:10.11005/jbm.2018.25.3.187.

35. Koo BK, Roh E, Yang YS, Moon MK. Difference between old and young adults in contribution of beta-cell function and sarcopenia in developing diabetes mellitus. Journal of diabetes investigation. 2016;7(2):233-40. doi:10.1111/jdi.12392.

36. Kim KS, Park KS, Kim MJ, Kim SK, Cho YW, Park SW. Type 2 diabetes is associated with low muscle mass in older adults. Geriatrics & gerontology international. 2014;14 Suppl 1:115-21. doi:10.1111/ggi.12189.

37. Han P, Kang L, Guo Q, Wang J, Zhang W, Shen S et al. Prevalence and Factors Associated With Sarcopenia in Suburb-dwelling Older Chinese Using the Asian Working Group for Sarcopenia Definition. The journals of gerontology Series A, Biological sciences and medical sciences. 2016;71(4):529-35. doi:10.1093/gerona/glv108.

38. Bouchi R, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I et al. Association of sarcopenia with both latent autoimmune diabetes in adults and type 2 diabetes: a cross-sectional study. J Diabetes Complications. 2017;31(6):992-6. doi:10.1016/j.jdiacomp.2017.02.021.

39. Trierweiler H, Kisielewicz G, Hoffmann Jonasson T, Rasmussen Petterle R, Aguiar Moreira C, Zeghbi Cochenski Borba V. Sarcopenia: a chronic complication of type 2 diabetes mellitus. Diabetology & metabolic syndrome. 2018;10:25. doi:10.1186/s13098-018-0326-5.

40. Kreidieh D, Itani L, El Masri D, Tannir H, Citarella R, El Ghoch M. Association between Sarcopenic Obesity, Type 2 Diabetes, and Hypertension in Overweight and Obese Treatment-Seeking Adult Women. Journal of cardiovascular development and disease. 2018;5(4). doi:10.3390/jcdd5040051.

41. Cuthbertson DJ, Bell JA, Ng SY, Kemp GJ, Kivimaki M, Hamer M. Dynapenic obesity and the risk of incident Type 2 diabetes: the English Longitudinal Study of Ageing. Diabetic medicine : a journal of the British Diabetic Association. 2016;33(8):1052-9. doi:10.1111/dme.12991.

42. Bouchi R, Fukuda T, Takeuchi T, Minami I, Yoshimoto T, Ogawa Y. Sarcopenia is associated with incident albuminuria in patients with type 2 diabetes: A retrospective observational study. Journal of diabetes investigation. 2017;8(6):783-7. doi:10.1111/jdi.12636.

43. Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PloS one. 2010;5(5):e10805.

44. Moon S-S. Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009-2010. Endocrine journal. 2013:EJ13-0244.

45. Handajani YS, Widjaja NT, Turana Y, Tengkawan J. Diabetes Mellitus, Adl Disability and Nutrition Intake: Determination Factors of Severe Sarcopenia among Elderly in Urban Nursing Homes. Indian Journal of Public Health Research & Development. 2018;9(3).

46. Bano G, Trevisan C, Carraro S, Solmi M, Luchini C, Stubbs B et al. Inflammation and sarcopenia: A systematic review and meta-analysis. Maturitas. 2017;96:10-5. doi:10.1016/j.maturitas.2016.11.006.

47. Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. Journal of Endocrinology. 2016;229(2):R67-R81.

48. Bourdel-Marchasson I, Helmer C, Fagot-Campagna A, Dehail P, Joseph PA. Disability and quality of life in elderly people with diabetes. Diabetes & metabolism. 2007;33:S66-S74.

49. SEO J, KIM S, KIM N, BAIK SH, CHOI DS, CHOI KM. Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes. Diabetes care. 2010;33(7):1497-9.

50. Lee CG, Boyko EJ, Strotmeyer ES, Lewis CE, Cawthon PM, Hoffman AR et al. Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. Journal of the American Geriatrics Society. 2011;59(7):1217-24.

51. Veronese N, Stubbs B, Fontana L, Trevisan C, Bolzetta F, De Rui M et al. Frailty Is Associated with an Increased Risk of Incident Type 2 Diabetes in the Elderly. Journal of the American Medical Directors Association. 2016;17(10):902-7. doi:10.1016/j.jamda.2016.04.021.

52. Guadarrama-López AL, Valdés-Ramos R, Martínez-Carrillo BE. Type 2 diabetes, PUFAs, and vitamin D: their relation to inflammation. Journal of immunology research. 2014;2014:860703-. doi:10.1155/2014/860703.

53. Can B, Kara O, Kizilarslanoglu MC, Arik G, Aycicek GS, Sumer F et al. Serum markers of inflammation and oxidative stress in sarcopenia. Aging clinical and experimental research. 2017;29(4):745-52.

54. Kirkham FA, Bunting E, Fantin F, Zamboni M, Rajkumar C. Independent Association Between Cardio‐Ankle Vascular Index and Sarcopenia in Older UK Adults. Journal of the American Geriatrics Society. 2019;67(2):317-22.

55. Prior SJ, Ryan AS, Blumenthal JB, Watson JM, Katzel LI, Goldberg AP. Sarcopenia is associated with lower skeletal muscle capillarization and exercise capacity in older adults. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2016;71(8):1096-101.

56. Kwan P. Sarcopenia, a neurogenic syndrome? Journal of aging research. 2013;2013:791679. doi:10.1155/2013/791679.

**FIGURE LEGENDS**

**Figure 1. Odds ratio of sarcopenia in diabetic participants vs. healthy controls**

**Figure 2. Adjusted odds ratio of diabetes in sarcopenia vs. healthy controls**

**Figure 3. Odds ratio of sarcopenia in diabetic people with micro or macro-complications vs. diabetics without complications.**

**Table 1. Descriptive characteristics of the studies included.**

| **Author, year** | **Country** | **Type of diabetes****(or complication)** | **Diabetes diagnosis** | **Diagnosis of sarcopenia** | **Sample size** | **Mean age** **(SD)** | **Mean** **BMI****(SD)** | **Covariates** | **NOS** | **Main findings** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bouchi, 2017 | Japan | LADA | PD | AWGS | 61 | 65 (10) | 24 (4.4) | Age, gender, BMI, HDL | 7 | Patients with LADA are at a high risk for sarcopenia compared tothose with T2DM or to control subjects |
| Bouchi, 2017 | Japan | Type 2 | PD | AWGS | 249 | 65 (10) | 25.4 (4.1) | Age, gender, BMI, HDL | 7 | Patients with LADA are at a high risk for sarcopenia compared tothose with T2DM or to control subjects |
| Bouchi, 2017\* | Japan | Albuminuria | PD | AWGS | 238 | 64 (12) | 25.4(4.1) | Age, gender, BMI, visceral fat area, insulin resistance | 5 | Sarcopenia is a significant important determinant of albuminuria in patients with T2DM |
| Çeliker, 2018 | Turkey | Nephropathy | PD | EWGSOP | 159 | 60.9 (6.9) | 31.4 (5.1) | Gender | 6 | The prevalence of sarcopenia was higher in patients with diabetic nephropathy compared to healthy controls |
| Cheng, 2017 | China | Diabetic foot | PD | Low SMI (<7 Kg men; 5.2 women) | 1105 | 66.6 (10.5) | 24.03 (3.55) | Gender, age, diabetes duration, diabetic foot duration, BMI, smoking, hypertension, creatinine, White Blood Cell, HbA1c, kidney disease, rethinopathy, neuropathy, peripheral arterial disease, medications (metformin, insulin secretagogues, insulin, ACEI/ARB and diuretics) | 5 | Sarcopenia is independently associated with diabetic foot |
| Cuthbertson, 2016\* | Ireland | Type 2 | PD | Lowest tertile of handgrip strength | 5953 | 65 (10) | 29.5(4.8) | Age, gender, BMI, smoking, alcohol, physical activity, depressive symptoms and prevalent cardiovascular disease  | 8 | Sarcopenia is associated with increased risk ofincident T2DM in older people |
| de Freitas,2018 | Brasil | Not specified | PD | EWGSOP | 76 | > 60 | NA | Sex, diabetes, beta-blockers use, cardiovascular disease, BMI, physical activity level, smoking habit  | 3 | Similar prevalence of diabetes in sarcopenia and controls  |
| Fukuda, 2017 | Japan | Retinopathy | PD | AWGS | 316 | 65 (12) | 24.3 (3.3) | Age, gender, BMI, body fat and the use of angiotensin receptor blockers  | 5 | Diabetic retinopathy association with sarcopenia and muscle quality in patients with T2DM   |
| Han, 2015 | China | Not specified | PD | AWGS | 769 | 67.3 (6) | 25.5(3.5) | Age, BMI, widowed, living alone, illiteracy, farming, drinking, diabetes, peptic ulcer, pulmonary disease  | 7 | Sarcopenia prevalence is significantly higher in males and not in females  |
| Handajani, 2018 | Indonesia | Not specified | PD | ASMMI <7.26 in men or 5.45 in women | 118 | 71.8 (7.9) | NA | Gender, diabetes mellitus, ADL-disability, carbohydrate and energy intake | 6 | Diabetes is a significant risk factor for severe sarcopenia |
| Kim 2014 | Korea | Type 2 | PD | ASMMI <7.40 in men or 5.14 in women | 810 | 71 (5) | 24.5 (3.5) | Age, BMI, current smoking, blood pressure, lipid levels | 6 | The risk of sarcopeniawas approximately two- to fourfold higher in older adults with T2DM |
| Koo, 2016 | Korea | Not specified | PD | Janssen criteria | 12792 | >45 | 24.2(3.5) | Age | 8 | Sarcopeniawas significantly associated with recent-onset diabetes only in patients aged≥75 years |
| Kreidieh, 2018 | Lebanon | Type 2 | PD | FNIH criteria | 184 | NA | 30.01 (5.57) | Lifestyle factors (i.e., sedentary lifestyle, fast-food consumption, and smoking) and central adiposity  | 8 | Sarcopenic obesity increases the odds of having T2DMby nearly 550% |
| Lim, 2018 | Korea | Not specified | PD | ASMMI<-1 SD of a reference population | 3492 | 68.8 (8.2) | NA | Age, gender, appendicular skeletal muscle, moderate physical activity, smoking, drinking, and nutrient intake  | 3 |  The sarcopenic-obesity group had the highest ratio of diabetes compared to the other groups |
| Ma, 2016 | USA | Type 2 | PD | 24 hr urine creatinine excretion | 769 | 69.7 | NA | Age, sex, ethinicy | 6 | Older adults with sarcopenic obesity had more adverse midlife cardiometabolic risks, particularlydiabetes 10 years earlier |
| Moon, 2013 | Korea | Not specified | PD | Janssen criteria | 10432 | 48.3 (15.5) | 23.5(3.2) | Age, sex, region, smoking, alcohol consumption, regular exercise, and family income  | 6 | Sarcopenia wasfound to be a risk factor for diabetes in the non-obese group |
| Murata, 2017 | Japan | Macroangiopathy | PD | AWGS | 288 | 73.3 (6.1) | 24.5(3.5) | Age and BMI | 5 | No difference of macroangiopathy in sarcopenia vs. controls  |
| Murata, 2017 | Japan | Retinopathy | PD | AWGS | 288 | 73.3 (6.1) | 24.5(3.5) | Age and BMI | 5 | No difference of retinopathy in sarcopenia vs. controls  |
| Srikanthan, 2010 | USA | Not specified | PD | FNIH criteria | 14528 | 45 | 26.3 (NA) | Age, sex, race, education. | 8 | Sarcopenia is associated with diabetes and the association isstrongest in individuals under 60 years of age  |
| Trierweiler, 2018 | Brazil | Type 2 | PD | FNIH and low handgrip strength | 166 | 65.9 (8.8) | 27.0(3.6) | BMI, dyslipidemia, healthy nutrition, osteoporosis, and past history of fractures  | 6 | Diabetes was associated with a higher prevalence of sarcopenia compared to control group |
| Wang 2015 | China | Type 2 | PD | AWGS | 1090 | 69.9 (8.1) | 24.0(3.6) | Age, gender, anti-diabetic medication, energy intake, protein intake, physical activity, and visceral fat area  | 8 | T2DM was significantly associated with increased risks ofsarcopenia and pre-sarcopenia |
| Yang, 2016 | China | Nephropathy | PD | ASMMI <7.26 in men or 5.45 in women | 793 | 51.53 (9) | 24.2(3.8) | Age, BMI, systolic and diastolic pressure, Hba1c, FPG, diabetes duration, smoking, drinking, drugs, physical activity  | 5 | Sarcopenia is associated with declining renal function |
| **Total** | **Asia: 14 studies; Europe: 2 studies; North America: 2 studies; South America: 2 studies.** | **7 studies: type 2 diabetes; 7 studies: not specified; 1 study: LADA; 6 studies: diabetes complications** |  | **6 studies: AWGS criteria; 5 studies: body composition criteria; 2 studies: EWGSOP; 2 studies: FNIH criteria; 1 study: low handgrip strength; 1 study: 24 h creatinine excretion** | **54676** | **65.4 (11.2)** | **25.0****(3.7)** |  | **Median=6 (range: 3-8)** |  |

 **\*** Longitudinal cohort study.

Abbreviations: LADA: latent autoimmune diabetes of adults; AWGS: Asian Working Group for Sarcopenia; EWGSOP: European Working Group on Sarcopenia in Older People; SMI: skeletal mass index; ASMMI: appendicular skeletal muscle mass index; FNIH: Foundation for the National Institutes of Health; PD: physician diagnosed; SD: standard deviation; BMI: body mass index.







**eFigure 1. PRISMA flow-chart.**

Studies included in quantitative synthesis (meta-analysis)
(n =17)

Records after duplicates removed
(n =953)

## Identification

Records identified through database searching
(n = 1020)

Additional records identified through other sources
(n = 0 )

## Included

## Eligibility

## Screening

Records excluded
(n =920)

)

Records screened
(n = 953)

Full-text articles excluded (n =13):

*-No sarcopenia (n=6);*

*-No diabetes (n=5);*

*-No meta-analyzable data (n=2)*

Full-text articles assessed for eligibility
(n = 33)

Studies included in qualitative synthesis
(n =20)